Clinical Trials Logo

Metastatic Cervical Cancer clinical trials

View clinical trials related to Metastatic Cervical Cancer.

Filter by:

NCT ID: NCT06313268 Recruiting - Clinical trials for Metastatic Colorectal Cancer

Safety of Effivia®, a Bevacizumab Biosimilar

Start date: April 21, 2022
Phase:
Study type: Observational [Patient Registry]

This is a post-marketing observational study aimed to evaluated the safety profile of Effivia®, a biosimilar of bevacizumab, in mexican patients with different types of cancer.

NCT ID: NCT06238635 Recruiting - Cervical Cancer Clinical Trials

Dostarlimab and Cobolimab in Advanced Cervical Cancer

Start date: March 11, 2024
Phase: Phase 2
Study type: Interventional

This research is being done to determine how effective dostarlimab in combination with cobolimab is in metastatic or recurrent cervical cancer.

NCT ID: NCT06157151 Recruiting - Cervical Cancer Clinical Trials

PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

Start date: June 2024
Phase: Phase 2
Study type: Interventional

This randomized trial will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab compared to pembrolizumab alone in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.

NCT ID: NCT05614453 Withdrawn - Clinical trials for Metastatic Cervical Cancer

Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy

ITTACC
Start date: June 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to learn about the effect of the combination treatment of sitravatinib with tislelizumab in patients with Recurrent/Metastatic Cervical Cancer after Platinum-Based Chemotherapy. The main question it aims to answer is the percentage of people in the study who have a partial or complete response to the treatment. Participants will receive treatment under the care of their treating physician and will be reviewed regularly.

NCT ID: NCT05446883 Recruiting - Clinical trials for METASTATIC CERVICAL CANCER

QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

Start date: September 23, 2022
Phase: Phase 3
Study type: Interventional

This study is a randomized, double-blind, placebo-controlled, multicenter phase III clinical study in 498 patients with persistent, recurrent or metastatic cervical cancer.Experimental: QL1706 + Chemotherapy (Paclitaxel-cisplatin/Carboplatin) ± Bevacizumab; Control group: placebo + chemotherapy (paclitaxel-cisplatin/carboplatin) ± bevacizumab

NCT ID: NCT04943627 Withdrawn - Advanced Cancer Clinical Trials

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

Start date: August 2, 2021
Phase: Phase 3
Study type: Interventional

This Phase 3 trial is an open-label, randomized study with single-agent Balstilimab (BAL) or Investigator Choice (IC) chemotherapy (single-agent gemcitabine, irinotecan, pemetrexed, vinorelbine, or topotecan) in patients with recurrent, persistent, or metastatic cervical cancer who have progressed after receiving platinum based chemotherapy.

NCT ID: NCT04865887 Recruiting - Cervical Cancer Clinical Trials

Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

Start date: October 7, 2022
Phase: Phase 2
Study type: Interventional

This is a phase II trial of combination therapy of pembrolizumab and lenvatinib in patients with locally advanced or metastatic cervical cancer that had failed first line of therapy. The hypothesis is the combination of lenvatinib and pembrolizumab will overcome vascular endothelial growth factor (VEGF)-mediated immunosuppression to enhance the response of patients with locally advanced or metastatic cervical cancer.

NCT ID: NCT04380805 Completed - Clinical trials for Recurrent Cervical Cancer

A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer

Start date: July 15, 2020
Phase: Phase 2
Study type: Interventional

This is a Phase 2, global, multicenter, open label, single arm study designed to evaluate the efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of AK104 monotherapy in adult subjects with previously treated recurrent or metastatic cervical carcinoma.

NCT ID: NCT04266886 Active, not recruiting - Clinical trials for Malignant Female Reproductive System Neoplasm

Self-Hypnosis for the Enhanced Recovery After Surgery in Patients With Gynecologic Cancer

Start date: September 11, 2018
Phase: N/A
Study type: Interventional

This trial studies how well self-hypnosis works in enhancing recovery after surgery in patients with gynecologic cancer. A guided relaxation method called self-hypnosis may help affect how patients feel pain and symptoms after surgery.

NCT ID: NCT04230954 Terminated - Cervical Cancer Clinical Trials

Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

Start date: April 16, 2020
Phase: Phase 2
Study type: Interventional

Drug: Cabozantinib Drug: Pembrolizumab